HVB MINI FUTURE BULL - ASTRAZENECA | Real-time Bid/Ask 12:25:32 07/05/2024 pm IST | ||
| 6.71 EUR / 6.75 EUR | +2.91% |
|
| Current month | -0.46% | ||
| 1 month | +32.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 6.54 | -0.76% | 0 |
| 03/24/03 | 6.59 | -1.49% | 0 |
| 02/24/02 | 6.69 | +1.83% | 0 |
| 30/24/30 | 6.57 | +0.31% | 0 |
| 29/24/29 | 6.55 | -0.46% | 0 |
Delayed Quote Börse Stuttgart
Last update May 07, 2024 at 12:19 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXV |
| ISIN | DE000HR5TXV8 |
| Date issued | 25/02/2021 |
| Strike | 6,403 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.1 € |
|---|---|
| Lowest since issue | 1.18 € |
| Spread | 0.04 € |
| Spread % | 0.59% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
163.6
USD
Spread / Average Target
+8.19%
- Stock Market
- Certificates
- Certificat